HUMA ▲ +5.0% - Humacyte, Inc.
$HUMA - Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
12-OCT-2026 08:00 AM ET
Share this post
More filings for $HUMA
HUMA ▲ +2.4% - Humacyte, Inc.Oct 23, 2026HUMA ▲ +5.7% - Humacyte, Inc.Oct 15, 2026HUMA ▲ +1.8% - Humacyte, Inc.Sep 28, 2026HUMA ▲ +1.7% - Humacyte, Inc.Sep 10, 2026HUMA ▲ +3.3% - Humacyte, Inc.Sep 9, 2026HUMA - Humacyte, Inc. - SEC Filing Update (18-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 18, 2026
View full $HUMA filing history →💬 Comments
Loading comments…
Leave a comment